Healthcare Stocks Had a Dismal Year. Therein Lies Opportunity, Says This Analyst
Goldman Sachs’ Asad Haider likes the prospects for medical technology companies, mid-cap biotechs, drug distributors.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Goldman Sachs’ Asad Haider likes the prospects for medical technology companies, mid-cap biotechs, drug distributors.